References
- Kernéis S, Valade S, Geri G, et al. Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis. 2015;47:789–795.
- Voor In't Holt AF, Severin JA, Lesaffre EM, et al. A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58:2626–2637.
- Patel G, Huprikar S, Factor SH, et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–1106.
- Weston G, Jacob JT, Ray S, et al. A multicenter study measuring appropriateness of carbapenem use. Infect Control Hosp Epidemiol. 2013;34:1324–1326.
- Yoon D, Koo HL, Choe PG, et al. The purpose and appropriateness of carbapenem use in a single university hospital, 2009–2013. Expert Rev Clin Pharmacol. 2016;9:863–865.
- Lefébure A, Papy E, Rioux C, et al. Audit of carbapenem prescriptions comparing 2 assessment periods. Med Mal Infect. 2015;45:273–278.
- Jary F, Kaiser JD, Henon T, et al. Appropriate use of carbapenems in the Besançon university hospital. Med Mal Infect. 2012;42:510–516.
- Apisarnthanarak A, Mundy LM. Inappropriate use of carbapenems in Thailand: a need for better education on de-escalation therapy. Clin Infect Dis. 2008;47:858–859.
- Goodlet KJ, Nailor MD. Necessity of carbapenem use when prescribed per infectious diseases specialists. Diagn Microbiol Infect Dis. 2017;88:41-46.
- Doi Y, Chambers HF. Other β-lactam antibiotics. In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Philadelphia (PA): Elsevier Inc; 2015. p. 293–297.